Scilex Holding (SCLXW) Share-based Compensation (2022 - 2026)
Scilex Holding (SCLXW) recorded quarterly Share-based Compensation of $3.6 million in Q1 2026, up 148.72% quarter-over-quarter from -$7.4 million in Q4 2025, and up 9.51% on a YoY basis from $3.3 million in Q1 2025.
Scilex Holding (SCLXW) Share-based Compensation (2022 - 2026) Analysis & Trends
Scilex Holding's Share-based Compensation history runs 5 years deep, the most recent figure standing at $3.6 million for Q1 2026.
- In Q1 2026, Share-based Compensation rose 9.51% year-over-year to $3.6 million; the TTM figure through Mar 2026 stood at $2.7 million (down 82.42% YoY), while the FY2025 annual figure was $2.4 million, down 84.7% from the prior year.
- Share-based Compensation was $3.6 million for Q1 2026 at Scilex Holding, up from -$7.4 million in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $4.8 million in Q4 2024 to a low of -$7.4 million in Q4 2025.
- Historically, Share-based Compensation has averaged $2.4 million across 5 years, with a median of $3.5 million in 2023.
- The sharpest annual moves came in 2023 and 2025: Share-based Compensation surged 201.92% in 2023, then tumbled 255.03% in 2025.
- A 5-year view of Share-based Compensation shows it stood at $1.3 million in 2022, then soared by 201.92% to $3.8 million in 2023, then grew by 27.02% to $4.8 million in 2024, then sank by 255.03% to -$7.4 million in 2025, then surged by 148.72% to $3.6 million in 2026.
- The last three Share-based Compensation figures came in at $3.6 million (Q1 2026), -$7.4 million (Q4 2025), and $3.3 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | - |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 161.00 Mn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 300.00 Mn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 444.00 Mn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | 185.00 Mn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 75.00 Mn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 218.00 Mn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 272.00 Mn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 146.00 Mn |
| 10 | Scilex Holding | - | - | 4.15 Mn | 3.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.63 Mn |
| Mar 31, 2026 | 3.63 Mn |
| Dec 31, 2025 | -7.45 Mn |
| Dec 31, 2025 | -7.45 Mn |
| Sep 30, 2025 | 3.26 Mn |
| Sep 30, 2025 | 3.26 Mn |
| Jun 30, 2025 | 3.28 Mn |
| Jun 30, 2025 | 3.28 Mn |
| Mar 31, 2025 | 3.31 Mn |
| Mar 31, 2025 | 3.31 Mn |
| Dec 31, 2024 | 4.81 Mn |
| Dec 31, 2024 | 4.81 Mn |
| Sep 30, 2024 | 3.71 Mn |
| Sep 30, 2024 | 3.71 Mn |
| Jun 30, 2024 | 3.61 Mn |
| Jun 30, 2024 | 3.61 Mn |
| Mar 31, 2024 | 3.56 Mn |
| Mar 31, 2024 | 3.56 Mn |
| Dec 31, 2023 | 3.78 Mn |
| Dec 31, 2023 | 3.78 Mn |